Results 151 to 160 of about 188,791 (289)

A single-center, observational, retrospective, case control study of rituximab for the treatment of interstitial pneumonia associated with autoimmune features. [PDF]

Front Pharmacol
Sandhu T, Meir L, Ng N, Klein L, Padilla M, Tassiulas I.   +5 more
europepmc   +1 more source

Novel Organelle‐Based Intracellular Immunity With Mechanistic and Therapeutic Implications

Barrier Immunity, EarlyView.
A conceptual framework illustrating how PAMPs/DAMPs initiate barrier, innate, adaptive, and intracellular immune responses, with organelle‐based intracellular immunity serving as a central integrator linking metabolism, inflammatory signaling, and therapeutic interventions to restore immune homeostasis.
Keman Xu, Shih‐Yu Hung, Fatma Saaoud, Ying Shao, Yifan Lu, Juanjuan Liu, Bo Yuan, Haiyan Xiang, Hong Wang, Xiaofeng Yang   +9 more
wiley   +1 more source

Rituximab combined with lenalidomide for the treatment of marginal zone lymphoma with IgM kappa positivity and cold agglutinin syndrome: a case report. [PDF]

Front Immunol
Zhang X, Zheng Y, Cai S.
europepmc   +1 more source

Exploring pathways leading to drug‐resistant epilepsy for patients with cryptogenic new onset refractory status epilepticus

Epilepsia, EarlyView.
Abstract Objective Cryptogenic new onset refractory status epilepticus (cNORSE) carries high risks of long‐term disability and post‐NORSE epilepsy, but mechanisms remain unclear. We aimed to assess the predictive value of inflammatory and brain injury biomarkers and determine whether immune disturbances persist in the chronic phase. Methods We enrolled
Aurélie Hanin, Clémence Marois, Martin Guillemaud, Mario Chavez, Léa Cosme, Zineb Hayatou, Aurore Besnard, Gwen Goudard, Véronique Masson, Louis Cousyn, Margaux Cheval, Jérôme A. Denis, Rana Alkouri, Foudil Lamari, Francesca Bisulli, Krista Eschbach, Raquel Farias‐Moeller, Nicolas Gaspard, Elizabeth E. Gerard, Giada Giovannini, Teneille Gofton, Margaret T. Gopaul, Marissa Kellogg, Stefano Meletti, Lorenzo Muccioli, Elena Pasini, Olga Taraschenko, Nathan Torcida, Mark S. Wainwright, Ji Yeoun Yoo, Nora Wong, Dominique Bonnefont‐Rousselot, Sophie Demeret, Lawrence J. Hirsch, Vincent Navarro   +34 more
wiley   +1 more source

Optimizing treatment for Waldenström macroglobulinemia-associated acquired von Willebrand syndrome: a case report and literature review. [PDF]

Front Oncol
Shen K, Yang C, Ma H.
europepmc   +1 more source

Daratumumab in relapse-refractory immune-mediated thrombotic thrombocytopenic purpura: additional evidence for its efficacy. [PDF]

Res Pract Thromb Haemost
Coppo P.
europepmc   +1 more source

Systemic anti‐cancer therapy associated with the occurrence of peripheral neurotoxicity and, specifically, peripheral neuropathy

International Journal of Cancer, EarlyView.
What's New? While the effectiveness of systemic anticancer therapy is well documented, it commonly causes severe toxicity. This study of the 467 systemic anticancer therapy agents currently approved globally for clinical and/or research purposes found that peripheral neurotoxicity is associated with 45% of classical chemotherapies, 21% of targeted ...
Cassie Higgins, Lynn R. Gauthier, Blair H. Smith, Lesley Colvin   +3 more
wiley   +1 more source

Impaired booster-induced SARS-CoV-2 antibody responses in rituximab-treated B-cell lymphoma patients despite peripheral B-Cell Recovery. [PDF]

Radiol Oncol
Jurca T, Boltezar L, Orazem M, Komlos KF, Pohar K, Jevnikar S, Poljak M, Mastnak DM, Kozjek NR, Vratanar B, Ocvirk J, Ihan A.   +11 more
europepmc   +1 more source

Efficacy and Safety Profile of a Rituximab, Methotrexate, and Thiotepa‐Based Regimen in Newly Diagnosed Primary CNS Lymphoma

International Journal of Cancer, EarlyView.
Primary central nervous system diffuse large B‐cell lymphoma (PCNS‐DLBCL) lacks an optimal first‐line induction strategy, particularly for older patients and those ineligible for intensive consolidation. In this retrospective cohort of 36 newly diagnosed patients, the rituximab + methotrexate + thiotepa (RMT) regimen as first‐line induction achieved ...
Haotian Wang, Jia Li, Luming Cao, Ying Zhang, Xin Wan, Xingtong Wang, Yangzhi Zhao, Zhaoxia Li, Chengqian Chen, Yang Song, Ou Bai   +10 more
wiley   +1 more source

Janus kinase inhibitor and rituximab in rheumatoid arthritis: is it a safe combination? [PDF]

Rheumatol Adv Pract
Rabee H, Mahto A.
europepmc   +1 more source